Rovi’s shares led the losses of the Ibex 35 in the early stages of the session this Wednesday and left 7.38%, until exchanging at a price of 37.9 euros, after announcing that it will increase its operating income by 5 % and 10% next year compared to those achieved in 2021.

However, the growth rate of operating income in 2023 will register a decrease in the low band of the second decade compared to 2022.

One of the main levers for growth will be manufacturing for third parties, which includes the acquisition of new customers, the increase in capacity and the agreement with Moderna.

In fact, Rovi and Moderna have extended their long-term collaboration for mRNA drug manufacturing over the next ten years.

The company announced a long-term collaboration with Moderna to increase formulation, aseptic filling, inspection, labeling and packaging capabilities at Rovi’s facilities in Madrid, San Sebasti√°n de los Reyes and Alcal√° de Henares.

This new agreement includes a series of investments that are expected to increase manufacturing capacity at Rovi’s facilities in Madrid.

In addition to producing Moderna’s Covid-19 vaccine, Rovi’s platform may also be used to service future Moderna mRNA vaccine candidates.

However, Rovi has recognized that in 2023 it is facing a new post-pandemic scenario of Covid-19 in which the uncertainty associated with the evolution of the disease is very high and therefore it is not possible to accurately assess the impact that this new scenario could have on its manufacturing business for third parties.

Apart from manufacturing for third parties, the new product distribution licenses, the launch and marketing of Okedi in Europe or the heparin division will boost Rovi’s growth.